tiprankstipranks
Trending News
More News >
Holista Colltech Limited (AU:HCT)
:HCT
Australian Market

Holista Colltech Limited (HCT) AI Stock Analysis

Compare
2 Followers

Top Page

AU

Holista Colltech Limited

(Sydney:HCT)

Rating:51Neutral
Price Target:
AU$0.00
▼(-100.00%Downside)
Holista Colltech Limited is facing significant financial difficulties, with declining revenues and negative equity being major concerns. While technical indicators show some short-term strength, the overall financial instability overshadows these positives. The stock's valuation is weak due to persistent losses, leading to a cautious outlook.

Holista Colltech Limited (HCT) vs. iShares MSCI Australia ETF (EWA)

Holista Colltech Limited Business Overview & Revenue Model

Company DescriptionHolista Colltech Limited (HCT) is a biotechnology company specializing in health and wellness solutions. Operating in sectors such as food ingredients, dietary supplements, and pharmaceutical-grade collagen, Holista Colltech focuses on developing innovative products aimed at enhancing health and improving quality of life. The company's core offerings include low-GI (glycemic index) food ingredients, natural dietary supplements, and collagen-based skincare products.
How the Company Makes MoneyHolista Colltech Limited generates revenue through the sale of its proprietary health and wellness products. Key revenue streams include its low-GI food ingredients, which are sold to food manufacturers and producers aiming to offer healthier food options, and its line of natural dietary supplements targeting various health concerns. The company also earns from its pharmaceutical-grade collagen, used in skincare and cosmetic products. Significant partnerships with food manufacturers, distributors, and retailers enhance its market reach, contributing to its earnings. Additionally, Holista Colltech may engage in licensing agreements and joint ventures to expand its product offerings and market presence.

Holista Colltech Limited Financial Statement Overview

Summary
Holista Colltech Limited faces significant financial challenges, marked by declining revenues, persistent net losses, negative equity, and unsustainable debt levels. Cash flow inefficiencies further highlight operational struggles.
Income Statement
35
Negative
Holista Colltech Limited shows a volatile income statement with declining revenue and persistent net losses over the years. The gross profit margin for 2024 is approximately 50.03%, which is reasonable. However, the net profit margin remains negative due to continued net losses. Revenue has decreased from $8.2 million in 2022 to $5.6 million in 2024, indicating a negative growth trend.
Balance Sheet
40
Negative
The balance sheet reveals financial distress, with a negative stockholders' equity of -$1.73 million in 2024, leading to an unsustainable debt-to-equity ratio. The company's total debt has been increasing, while assets are declining, indicating a potential risk of insolvency. The equity ratio is negative due to the negative equity, highlighting financial instability.
Cash Flow
30
Negative
Cash flow statements indicate challenges, with negative operating cash flow and negative free cash flow persistently over the years. The free cash flow growth rate is negative, showing no improvement in cash generation. The operating cash flow to net income ratio is unfavorable, reflecting inefficiencies in converting revenue into cash.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue5.60M5.95M8.24M8.02M7.11M
Gross Profit2.80M2.62M1.01M1.31M873.15K
EBITDA304.37K-4.52M-1.02M-957.40K-5.30M
Net Income-84.21K-4.81M-1.45M-1.26M-5.48M
Balance Sheet
Total Assets3.34M3.35M5.52M6.93M8.05M
Cash, Cash Equivalents and Short-Term Investments21.72K59.77K117.53K1.21M2.73M
Total Debt1.77M1.57M1.22M890.32K942.70K
Total Liabilities6.71M6.74M3.96M3.95M3.41M
Stockholders Equity-1.73M-1.97M2.83M4.10M5.42M
Cash Flow
Free Cash Flow-1.02M-411.67K-1.19M-1.72M-3.90M
Operating Cash Flow-1.01M-407.12K-1.11M-1.68M-3.87M
Investing Cash Flow692.12K-46.70K-105.69K50.35K-80.75K
Financing Cash Flow116.24K418.42K120.85K109.49K6.58M

Holista Colltech Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.06
Price Trends
50DMA
0.05
Positive
100DMA
0.04
Positive
200DMA
0.03
Positive
Market Momentum
MACD
<0.01
Positive
RSI
56.44
Neutral
STOCH
132.28
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HCT, the sentiment is Positive. The current price of 0.06 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.05, and above the 200-day MA of 0.03, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 56.44 is Neutral, neither overbought nor oversold. The STOCH value of 132.28 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:HCT.

Holista Colltech Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AUHCT
51
Neutral
AU$18.76M
-5.86%98.26%
AUMBH
50
Neutral
AU$23.38M-33.40%-13.09%-139.06%
49
Neutral
AU$2.50B4.42-64.25%2.77%36.51%13.14%
AUOMG
42
Neutral
AU$5.10M-76.28%5.01%74.84%
AUWNX
39
Underperform
€17.62M-240.42%14.41%76.26%
AUEVE
34
Underperform
AU$8.62M-105.17%-3.82%51.47%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:HCT
Holista Colltech Limited
0.06
0.05
500.00%
AU:WNX
Wellnex Life Ltd
0.26
-1.10
-80.87%
AU:EVE
EVE Health Group Limited
0.04
0.01
33.33%
AU:OMG
Forbidden Foods Ltd
0.01
0.00
0.00%
AU:MBH
Maggie Beer Holdings Ltd.
0.07
0.01
16.67%

Holista Colltech Limited Corporate Events

Holista Colltech Confirms Mr. Leong Man Loong as Permanent CEO
Jul 2, 2025

Holista Colltech Limited has appointed Mr. Leong Man Loong as the permanent Chief Executive Officer, following his interim leadership since January 2025. Mr. Leong’s strategic focus and commitment to the company’s recovery have been recognized by the Board, who have confirmed his role with a nominal remuneration of $1 per annum. This decision underscores Holista’s strategy to rebuild shareholder value and strengthen its market position in the health and wellness industry.

Holista Colltech Issues New Shares Following Convertible Note Conversion
Jun 17, 2025

Holista Colltech Limited has announced the issuance of 49,281,936 fully paid ordinary shares following the conversion of convertible notes, as approved by its shareholders. This move, conducted without disclosure under Part 6D.2 of the Corporations Act, signifies compliance with relevant legislative provisions and indicates no undisclosed information, potentially impacting investor confidence and market positioning.

Holista Colltech Limited Announces Quotation of New Securities
Jun 17, 2025

Holista Colltech Limited has announced the application for the quotation of 49,281,936 ordinary fully paid securities on the ASX, as part of previously announced transactions. This move is expected to enhance the company’s liquidity and market presence, potentially benefiting stakeholders by increasing the company’s visibility and access to capital.

Holista Colltech Updates on Nano-Collagen Licensing Discussions
May 29, 2025

Holista Colltech Limited announced at its AGM that it is in ongoing discussions with Regenerex regarding a licensing agreement for Nano-Collagen marketing, though no binding agreement has been reached yet. The company cautions investors against making decisions based on the assumption that an agreement will be finalized, highlighting the uncertainty of the negotiations’ outcome.

Holista Colltech Limited Announces AGM Results with Strong Shareholder Support
May 29, 2025

Holista Colltech Limited, a company listed on the Australian Securities Exchange under the code HCT, held its Annual General Meeting on May 29, 2025. The meeting’s resolutions were decided by poll, with the results showing strong support for most resolutions, including the election of directors and approval of various mandates and securities issues. The outcomes indicate a stable shareholder confidence in the company’s strategic decisions and governance.

Holista Colltech Shifts Focus to Advanced Nano-Collagen Applications
May 27, 2025

Holista Colltech Limited has announced a strategic shift in its ovine collagen business, including the closure of its Collie facility and plans to establish a new modular production model. The company is focusing on developing nano-collagen for advanced medical applications, such as wound healing and bio-ink for organ printing, and has partnered with Akrivis Health Care to enhance its nano-collagen capabilities. Holista is also working on securing intellectual property rights and expanding its market presence through a proposed license agreement with Regenerex Pharma Inc. for international markets.

Holista Colltech Appoints New Director to Strengthen Leadership
May 16, 2025

Holista Colltech Limited has announced the appointment of Yuen Keong Yee as a director, effective May 14, 2025. This appointment is part of the company’s ongoing efforts to strengthen its leadership team, although the new director currently holds no securities in the company. The announcement is expected to have implications for the company’s strategic direction and governance, potentially impacting its market positioning and stakeholder relations.

Holista Colltech Announces Strategic Board Appointments
May 14, 2025

Holista Colltech Limited has announced the appointment of Mr. Robert Gemelli and Mr. Sam Yee as Independent Non-Executive Directors, following the resignations of Mr. David Deloub and Ms. Loren King. This strategic change in leadership is expected to bring valuable expertise in biotech commercialization and capital markets, aiding the company in advancing its pipeline and focusing on corporate recovery. The new directors’ diverse backgrounds in various industries are anticipated to strengthen Holista’s board and support its mission to deliver sustainable, science-backed health and wellness solutions.

Holista Colltech Addresses ASX Price Query
May 12, 2025

Holista Colltech Limited has responded to a price query from ASX, confirming that it is not aware of any undisclosed information that could explain recent trading activity in its securities. The company assures compliance with ASX Listing Rules and confirms that its board has authorized the responses provided.

Holista Colltech Limited Announces 2025 Annual General Meeting
Apr 30, 2025

Holista Colltech Limited has announced its Annual General Meeting scheduled for May 29, 2025, at Stantons International in West Perth. The meeting will cover the financial statements and reports for the year ending December 31, 2024, and include several resolutions such as the adoption of the remuneration report, election and re-election of directors, and ratification of prior securities issues. These resolutions are significant for the company’s governance and financial structuring, impacting shareholder interests and the company’s strategic direction.

Holista Colltech Resolves ASIC Matter and Focuses on Recovery
Apr 29, 2025

Holista Colltech Limited has successfully resolved its regulatory issues with ASIC by completing a $900K penalty payment. The company raised $1.53 million through convertible notes to settle this penalty and support working capital. Despite facing increased manufacturing costs and cash flow challenges, Holista recorded $1.9 million in customer receipts and $1.8 million in group sales, largely driven by its Dietary Supplements Division. The company is now focused on corporate recovery, stabilizing operations, and strengthening its financial position.

Holista Colltech Updates on Equity Securities Conversion
Apr 28, 2025

Holista Colltech Limited has announced an update regarding the conversion of unquoted equity securities, specifically adjusting the amount of converting notes. This update reflects the company’s ongoing financial management and could have implications for its capital structure and investor relations.

Holista Colltech Appoints New Chairperson to Drive Strategic Growth
Apr 23, 2025

Holista Colltech Limited has appointed Mr. Lai Kwok Kin as the new Independent, Non-Executive Chair of the Board. Mr. Lai, who has been an independent Non-Executive Director since March 2024, brings expertise in investor relations and corporate strategy. His appointment follows the resignations of the previous Chair, Mr. David Deloub, and Director, Ms. Loren King. This leadership change is seen as a strategic move to strengthen Holista’s governance and drive sustainable growth.

Holista Colltech Issues Unquoted Equity Securities
Apr 17, 2025

Holista Colltech Limited has announced the issuance of unquoted equity securities, specifically converting notes, totaling 1,105,262 units. These securities are part of previously announced transactions and are not intended to be quoted on the ASX, indicating a strategic move by the company to manage its equity structure and potentially raise capital.

Holista Colltech Addresses Late Filing of Director’s Interest Notice
Apr 17, 2025

Holista Colltech Limited announced a late filing of an Initial Director’s Interest Notice for newly appointed director Gregory Pilant, due to an administrative oversight. The company reassures stakeholders that it maintains adequate disclosure procedures and that this incident was an isolated oversight, not indicative of systemic issues.

Leadership Changes at Holista Colltech Limited
Apr 16, 2025

Holista Colltech Limited announced the resignation of Non-Executive Chair David Deloub and Non-Executive Director Loren King, who have provided four weeks’ notice for personal reasons. The company plans to appoint new directors within this period. This change in leadership comes as Holista continues its mission to innovate in the biotech industry, focusing on natural health solutions and advanced collagen technologies, potentially impacting its strategic direction and stakeholder interests.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 03, 2025